secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001490978-22-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrodinger Q3 rev $37M (+24% YoY); Lilly collab up to $425M; FY22 guide narrowed
--------------------------------------------------------------------------------

- Q3 total revenue $37.0M (+24% YoY); drug discovery $12.3M (+121%); software $24.7M (+2%)
- Net loss $39.9M vs $35.0M; cash $479M vs $513M at June 30, 2022
- Entered collaboration with Lilly; up to $425M in milestones plus tiered royalties
- Phase 1 trial of MALT1 inhibitor SGR-1505 open for patient enrollment
- FY22 total revenue guide narrowed to $167-175M; software rev lowered to $122-127M; drug discovery raised to $45-48M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/0001490978-22-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/sdgr-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001490978-22-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer